Real-world data on potent P2Y12-inhibition in patients with suspected chronic coronary syndrome, referred for coronary angiography
Conclusion
In patients with CCS referred for CA and PCI if feasible, a more potent P2Y12 inhibition strategy with ticagrelor was not associated with bleeding complications or MACE compared with clopidogrel.
Source: Cardiology - Category: Cardiology Source Type: research
More News: Angiography | Angioplasty | Bleeding | Cardiology | Cardiovascular | Clopidogrel | Coronary Angioplasty | Heart | Heart Attack | Percutaneous Coronary Intervention | Plavix | Statistics | Stroke | Study | Thrombosis